awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26768679-B5D0849E-7CD2-4B65-BFEE-2A3C743E80F6
Q26768679-B5D0849E-7CD2-4B65-BFEE-2A3C743E80F6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26768679-B5D0849E-7CD2-4B65-BFEE-2A3C743E80F6
DNA repair targeted therapy: The past or future of cancer treatment?
P2860
Q26768679-B5D0849E-7CD2-4B65-BFEE-2A3C743E80F6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26768679-B5D0849E-7CD2-4B65-BFEE-2A3C743E80F6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
704dd709a343fdd6d805c7a89c334a518c559a72
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer